Explore the unique mechanisms of bispecific antibodies versus CAR T-cell therapies in treating multiple myeloma and their clinical implications. In this episode, experts begin outlining how bispecific ...
An international research consortium, led by scientists at VIB and UGent, has developed a new platform that could change how ...
Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...
Heparin-induced thrombocytopenia (HIT) is an immune-mediated platelet disorder caused by antibodies that target complexes of platelet factor 4 (PF4) and heparin. HIT has been characterized as a ...
Researchers at Colorado State University have determined how to use artificial intelligence to modify antibodies so they act ...
B-cell depletion is effective in MS and NMOSD, with anti-CD20 and anti-CD19 mAbs showing distinct mechanisms impacting safety and tolerability. Glycoengineering enhances ADCC activity, mitigating ...
Bispecific antibodies enhance immune response by targeting myeloma and immune cells, showing high efficacy in multiple myeloma treatment. Tecvvayli, Talvey, and Elrexfio demonstrate significant ...
In less than a decade, bispecific antibodies have gone from scientific curiosity to frontline cancer therapeutics. These engineered proteins, capable of binding to two or more targets simultaneously, ...
Specific antibody deficiency (SAD) is an immune system disorder. It occurs when you have normal levels of antibodies but an insufficient immune response to certain types of bacteria. Antibodies, also ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results